Calliditas Therapeutics AB

CALTX

SE0010441584

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 10:51:17 2024-04-25 am EDT			5-day change	1st Jan Change
102.4 ^SEK	+1.94%		+0.49%	-19.35%

Apr. 24	Calliditas Therapeutics Says OLE Study Shows Treatment Response Consistent With Late-Stage NefIgArd Study's Findings	MT
Apr. 24	Calliditas Therapeutics AB Announces Positive NefIgArd Open Label Extension Results	CI

Calliditas Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2022

May 18, 2022 at 01:00 am EDT

Calliditas Therapeutics AB (publ) reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was SEK 49.73 million. Net loss was SEK 207.05 million compared to SEK 130.87 million a year ago. Basic loss per share from continuing operations was SEK 3.95 compared to SEK 2.62 a year ago.

Latest news about Calliditas Therapeutics AB

Calliditas Therapeutics Says OLE Study Shows Treatment Response Consistent With Late-Stage NefIgArd Study's Findings	Apr. 24	MT
Calliditas Therapeutics AB Announces Positive NefIgArd Open Label Extension Results	Apr. 24	CI
European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading	Apr. 22	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	Apr. 19	MT
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024	Apr. 18	CI
Calliditas Therapeutics AB Presents Additional Data Analyses from the Phase 3 NeflgArd Trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024	Apr. 18	CI
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Apr. 17	MT
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	Apr. 15	MT
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading	Apr. 12	MT
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading	Apr. 11	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Apr. 10	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	Apr. 09	MT
Calliditas Therapeutics AB to Present Nefecon Data At the ISN World Congress of Nephrology in Buenos Aires	Apr. 08	CI
Calliditas Therapeutics Gets US Patent Allowance for Cancer Treatment Inhibitor	Apr. 08	MT
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Close Out Week Lower	Apr. 05	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading	Apr. 04	MT
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Wednesday Trading	Mar. 27	MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading	Mar. 25	MT
European Equities Traded in the US as American Depositary Receipts Start Week Slightly Lower in Monday Trading	Mar. 18	MT
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading	Mar. 13	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading	Mar. 12	MT
Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®	Mar. 11	CI
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday	Mar. 06	MT
Calliditas Therapeutics Gets US FDA Orphan Drug Exclusivity for Kidney Disease Drug	Mar. 06	MT
Calliditas Therapeutics Says Kidney Disease Drug Granted Seven-Year Exclusivity Period by FDA	Mar. 06	MT

Chart Calliditas Therapeutics AB

Duration

Period

More charts

Company Profile

Calliditas Therapeutics AB, formerly Pharmalink AB, is a Sweden-based specialty pharmaceutical company. It is focused on the development and commercialization of its product candidate Nefecon, a treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Nefecon is derived from the TARGIT technology, in which the capsule containing the active drug substance is coated in a way that the capsule remains intact as it passes through the stomach and intestine until it reaches the lower small intestine, where the release of content takes place. Nefeco combines time lag effect with a concentrated release of the active substance budesonide, within a designated target area.

Sector

Pharmaceuticals

Calendar

2024-04-24 - World Orphan Drug Congress

More about the company

Income Statement Evolution

More financial data

Ratings for Calliditas Therapeutics AB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

100.4 SEK

Average target price

208 SEK

Spread / Average Target

+107.17%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
CALLIDITAS THERAPEUTICS AB	-19.35%	495M
MERCK KGAA	+4.06%	70.78B
KYOWA KIRIN CO. LTD.	+10.72%	9.15B
SK BIOPHARMACEUTICALS CO., LTD.	-15.34%	4.84B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+34.54%	4.22B
YUHAN CORPORATION	+5.09%	3.92B
INDIVIOR PLC	+16.03%	2.55B
BETTA PHARMACEUTICALS CO., LTD.	-24.15%	2.26B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-28.33%	2.24B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+6.23%	1.92B

Specialty & Advanced Pharmaceuticals